New York State Common Retirement Fund boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 20.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 83,800 shares of the biotechnology company’s stock after buying an additional 14,499 shares during the period. New York State Common Retirement Fund owned 0.10% of BioCryst Pharmaceuticals worth $466,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Principal Financial Group Inc. lifted its holdings in BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after buying an additional 45 shares during the period. Legal & General Group Plc lifted its holdings in BioCryst Pharmaceuticals by 4.9% in the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after buying an additional 860 shares during the period. Fox Run Management L.L.C. purchased a new stake in BioCryst Pharmaceuticals in the second quarter worth about $126,000. Bank of America Corp DE lifted its holdings in BioCryst Pharmaceuticals by 43.3% in the first quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock worth $210,000 after buying an additional 7,568 shares during the period. Finally, Janney Montgomery Scott LLC lifted its holdings in BioCryst Pharmaceuticals by 4.7% in the second quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock worth $185,000 after buying an additional 1,500 shares during the period. Institutional investors and hedge funds own 71.30% of the company’s stock.
In related news, Director Fred E. Cohen sold 54,250 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $5.42, for a total transaction of $294,035.00. Following the completion of the sale, the director now owns 173,660 shares of the company’s stock, valued at $941,237.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.60% of the stock is owned by company insiders.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) opened at $4.76 on Tuesday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $3.95 and a 1-year high of $9.25. The company has a current ratio of 2.53, a quick ratio of 2.53 and a debt-to-equity ratio of 0.21.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). The company had revenue of $8.76 million during the quarter, compared to the consensus estimate of $5.05 million. BioCryst Pharmaceuticals had a negative net margin of 167.58% and a negative return on equity of 123.16%. The firm’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.16) earnings per share. research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.
Several analysts have commented on BCRX shares. Piper Jaffray Companies restated an “overweight” rating and issued a $15.00 price objective (up from $13.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 5th. Noble Financial restated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. ValuEngine upgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, September 6th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. BioCryst Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $9.13.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.